Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;19(2):114-131.
doi: 10.1038/s41571-021-00579-w. Epub 2021 Nov 24.

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Giulia Petroni  1 , Lewis C Cantley  2   3 , Laura Santambrogio  1   3   4 , Silvia C Formenti  1   2   3 , Lorenzo Galluzzi  5   6   7
Affiliations
Review

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Giulia Petroni et al. Nat Rev Clin Oncol. 2022 Feb.

Erratum in

Abstract

A variety of targeted anticancer agents have been successfully introduced into clinical practice, largely reflecting their ability to inhibit specific molecular alterations that are required for disease progression. However, not all malignant cells rely on such alterations to survive, proliferate, disseminate and/or evade anticancer immunity, implying that many tumours are intrinsically resistant to targeted therapies. Radiotherapy is well known for its ability to activate cytotoxic signalling pathways that ultimately promote the death of cancer cells, as well as numerous cytoprotective mechanisms that are elicited by cellular damage. Importantly, many cytoprotective mechanisms elicited by radiotherapy can be abrogated by targeted anticancer agents, suggesting that radiotherapy could be harnessed to enhance the clinical efficacy of these drugs. In this Review, we discuss preclinical and clinical data that introduce radiotherapy as a tool to elicit or amplify clinically actionable signalling pathways in patients with cancer.

PubMed Disclaimer

Figures

Fig. 1 ∣
Fig. 1 ∣. Cytoprotective pathways elicited by radiotherapy.
Ionizing radiation damages a variety of macromolecules including nuclear DNA, either directly or upon generation of reactive oxygen species. Such damage is often detected by a molecular complex encompassing meiotic recombination 11 (MRE11), DNA repair protein Rad50 (RAD50) and Nijmegen breakage syndrome 1 (NSB1) in co-operation with members of the poly(ADP-ribose) polymerase (PARP) protein family. Formation of this complex results in the sequential activation of ATM, CHEK2 and p53. Alternatively or concomitantly, the DNA damage induced by radiotherapy drives the activation of ATR and consequently CHEK1, DNA-dependent protein kinase (DNA-PK) or WEE1 signalling. Ultimately, these pathways converge on the inhibition of cyclin-dependent kinases (CDKs) resulting in arrested cell-cycle progression at specific checkpoints, which enables DNA repair and hence supports radioresistance (part a). The DNA damage response elicited by radiotherapy also promotes (directly or indirectly) the hyperactivation of PI3K signalling, resulting in the delivery of cytoprotective signals via AKT1 and MTOR (part b), the activation of autophagy (which is generally under negative regulation by MTOR) (part c), as well as the synthesis, secretion and activation of transforming growth factor-β1 (TGFβ1) (part d). GPCR, G-protein-coupled receptor; LAP, latency associated peptide; LTBP1, latent transforming growth factor-β binding protein 1; PTEN, phosphatase and tensin homologue; RTK, receptor tyrosine kinase.
Fig. 2 ∣
Fig. 2 ∣. Targeting the pro-survival pathways induced by radiotherapy in cancer.
At least in part owing to intratumoural heterogeneity, radiotherapy alone is often unable to kill all malignant cells and thus does not mediate complete tumour eradication. In this setting, cancer cells generally resist the cytostatic and/or cytotoxic effects of radiotherapy along with the activation of various cytoprotective signalling pathways. Importantly, such cytoprotective pathways establish a state of non-oncogene addition that can be targeted using specific agents in order to achieve superior disease control.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bedard PL, Hyman DM, Davids MS & Siu LL Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395, 1078–1088 (2020). - PubMed
    1. Boumahdi S & de Sauvage FJ The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov 19, 39–56 (2020). - PubMed
    1. Sotorasib edges closer to approval. Cancer Discov. 11, OF2 (2021). - PubMed
    1. Doroshow DB et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol 18, 345–362 (2021). - PubMed
    1. Luo J, Solimini NL & Elledge SJ Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009). - PMC - PubMed

Publication types